Page 93 - Read Online
P. 93

Sulaiman et al. J Transl Genet Genom 2020;4:159-87  I  https://doi.org/10.20517/jtgg.2020.27                                          Page 179

               Table 3. mtDNA tests available on the market
                                                     Year founded,
               Company                URL                                 Method         Main purpose of test
                                                       location
               Centogene     https://www.centogene.com   2006, UK  Whole-exome sequencing  Genealogy
               GeneDX        https://www.genedx.com    2000
               Family Tree DNA  http://www.familytreedna.com   1999, USA  Next-generation sequencing   Mitochondrial DNA analysis
                                                                  2000x coverage        - limited hypervariable region
                                                                                        test or full sequence test
               Gene Base Systems,  https://www.genebase.com   2005, Vancouver, British,  Advanced fluorescent probe   Genealogy
               Inc                                Columbia, Canada  technology for sequencing DNA
               23andMe, Inc  https://www.23andme.com   2006, California  Illumina Global Screening Array  Ancestry, DNA relatives
                                                                  (GSA) customized chip
               YSEQ          https://www.yseq.net/   2013         Sequencing            Ancestry
               Full Genomes   https://www.fullgenomes.com    2013, USA  Next-generation sequencing  Focusing on the Y
               Corporation                                                              chromosome and WGS
               Living DNA    https://livingdna.com   2016, England, UK  Next-generation sequencing  Y-DNA, mtDNA haplogroup
               Oxford Ancestors  http://www.oxfordancestors.com  2000, England, UK  Next-generation sequencing  mtDNA, Y chromosome

               a comprehensive detection strategy with high sensitivity and specificity. Early identification of affected
               individuals is important for the patient’s outcome, as early treatment will result in a better prognosis.
               Importantly, with a simple blood sampling, the cascade screening of the family members can be done with
               the same strategy.

               DECLARATIONS
               Authors’ contributions
               Wrote the manuscript and revised the manuscript for intellectual content: Sulaiman SA
               Wrote a few parts of the manuscript: Mohd Rani Z, Radin FZM
               Planned and wrote the manuscript and also revised the manuscript for intellectual content: Abdul Murad NA


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               None.


               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2020.

               REFERENCES
               1.   Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, et al. Mitochondrial diseases. Nat Rev Dis Primers 2016;2:16080.
               2.   DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol 2013;9:429-44.
               3.   Duran J, Martinez A, Adler E. Cardiovascular manifestations of mitochondrial disease. Biology 2019;8:34.
               4.   Zong WX, Rabinowitz JD, White E. Mitochondria and Cancer. Mol Cell 2016;61:667-76.
               5.   McCormick EM, Muraresku CC, Falk MJ. Mitochondrial Genomics: a complex field now coming of age. Curr Genet Med Rep
   88   89   90   91   92   93   94   95   96   97   98